Price T Rowe Associates Inc Intellia Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

$836 Billion
Q2 2024

A detailed history of Price T Rowe Associates Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,244,959 shares of NTLA stock, worth $21.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,244,959

Previous 1,625,051 23.39%

Holding current value

$21.8 Million

Previous $44.7 Million 37.68%

% of portfolio

0.0%

Previous 0.01%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$20.02 - $27.22 $7.61 Million - $10.3 Million	-380,092 Reduced 23.39%	1,244,959 $27.9 Million
Q1 2024 May 15, 2024	SELL	$23.82 - $32.8 $4.98 Million - $6.86 Million	-209,092 Reduced 11.4%	1,625,051 $44.7 Million
Q4 2023 Feb 14, 2024	SELL	$23.16 - $32.34 $4.98 Million - $6.96 Million	-215,077 Reduced 10.5%	1,834,143 $55.9 Million
Q3 2023 Nov 14, 2023	SELL	$31.62 - $45.78 $356,389 - $515,986	-11,271 Reduced 0.55%	2,049,220 $64.8 Million
Q2 2023 Aug 14, 2023	BUY	$34.58 - $46.03 $6.6 Million - $8.78 Million	190,730 Added 10.2%	2,060,491 $84 Million
Q1 2023 May 15, 2023	SELL	$33.3 - $44.82 $1.98 Million - $2.67 Million	-59,594 Reduced 3.09%	1,869,761 $69.7 Million
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $6.38 Million - $12 Million	192,095 Added 11.06%	1,929,355 $67.3 Million
Q3 2022 Nov 14, 2022	SELL	$53.92 - $71.7 $16.7 Million - $22.2 Million	-310,071 Reduced 15.15%	1,737,260 $97.2 Million
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $6.64 Million - $13.1 Million	-172,540 Reduced 7.77%	2,047,331 $106 Million
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $6.96 Million - $14.2 Million	119,523 Added 5.69%	2,219,871 $161 Million
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $24.6 Million - $33.8 Million	-244,190 Reduced 10.42%	2,100,348 $248 Million
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $18.8 Million - $25.1 Million	-141,953 Reduced 5.71%	2,344,538 $315 Million
Q2 2021 Aug 16, 2021	BUY	$60.88 - $161.91 $9.86 Million - $26.2 Million	162,001 Added 6.97%	2,486,491 $403 Million
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $9.49 Million - $17 Million	203,607 Added 9.6%	2,324,490 $187 Million
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $39.9 Million - $135 Million	2,120,883 New	2,120,883 $115 Million

Others Institutions Holding NTLA

# of Institutions

319

Shares Held

88.7M

Call Options Held

668K

Put Options Held

865K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.33B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Intellia Therapeutics, Inc. Transaction History